Is Florida on the list of states expected to see northern lights on Tuesday night?
The National Oceanic and Atmospheric Administration (NOAA) upgraded its geomagnetic storm watch for June 25 and 26, and as many as 14 states could catch a glimpse of the northern lights overnight on Tuesday into Wednesday.
Unfortunately for Floridians, the Sunshine State isn't on the list.
NOAA's Space Weather Prediction Center's latest three-day forecast shows that a hole in the sun's atmosphere will be directed toward Earth, sparking a stream of solar wind toward the pale blue dot.
The storm's Kp index is about a five for Tuesday and Wednesday night, indicating that the northern lights will be 'brighter and there will be more auroral activity' for the places that can see them.
Parts of the United States encompassing about 14 states will be able to catch a glimpse of aurora borealis:
Northern Idaho
Iowa
Maine
Michigan
Minnesota
Montana
New Hampshire
New York
North Dakota
South Dakota
Vermont
Washington
Wisconsin
Wyoming
Florida and the northern lights aren't exactly well acquainted, but they do cross paths in rare occasions.
The northern lights were spotted in Florida twice in 2024: First in May and then again in November, thanks to a pair of powerful solar storms.
Though rare, Florida has seen northern lights before 2024.
In 1989, the aurora borealis appeared on the First Coast and was visible in a red glow tinged with pale green and white streaks, the Florida Times-Union reported.
Northern lights were visible as far as South Florida in 1981, though reports indicate they were much less impressive.
Then there was the Carrington Event of 1859 tinting the sky bright red and green, which may have been the most powerful solar flare on record, according to NOAA.
Contributors: Cheryl McCloud, Eric Lagatta — USA TODAY NETWORK - Florida
This article originally appeared on Pensacola News Journal: Florida not on the list to see northern lights tonight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Kratom Consumer Advisory Council (KCAC) Releases White Paper Refuting HART's Misleading Claims on Synthetic 'Gas Station Heroin' and Opioid Mortality Rates
'HART's argument isn't just scientifically unsupported—it's dangerous,' stated Dr. C. Michael White, UCONN Kratom Consumer Advisory Council (KCAC) today released a comprehensive position paper, " Fact Check on Synthetic 7 Solving the Opioid Crisis,' refuting the Holistic Alternative Recovery Trust's (HART) claim and that of its National Policy Director Jeff Smith (media clip here ) that synthetic 7-hydroxymitragynine ('synthetic 7') products have reduced the opioid mortality death rate in the United States. This claim, which HART has presented in testimony to lawmakers in multiple states and to media outlets, is not supported by any published clinical trials or peer-reviewed observational studies. In contrast, the KCAC's position paper outlines overwhelming evidence pointing to community naloxone distribution and public health partnerships as the true drivers of reduced opioid deaths. 'HART's argument isn't just scientifically unsupported—it's dangerous,' said Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, a pharmacist, distinguished professor of pharmacy practice at the University of Connecticut School of Pharmacy, and KCAC chair. 'The reduction in opioid mortality in recent years correlates most clearly with community-based naloxone access and training initiatives, not the rise of potent, unregulated synthetic opioids being sold in gas stations and smoke shops.' The KCAC white paper highlights well-documented evidence from public health literature: Unlike whole-leaf kratom and natural mitragynine—which preclinical studies suggest have a low risk of respiratory depression—synthetic 7 and similar analogs (including tianeptine and mitragynine pseudoindoxyl) have been shown in multiple animal studies to significantly depress respiratory function at high doses. These effects mirror those of morphine and respond poorly to naloxone reversal—underscoring their danger to public health. Further, anecdotal reports suggest that synthetic 7 products have caused severe addiction, and the rapid tolerance requires consumers to escalate doses over time. In addition, their bright packaging and candy-like branding (e.g., 'Perks,' 'Opia,' 'Rave') may appeal to children and teens—raising additional concerns among parents and policymakers. Leading kratom researchers at Johns Hopkins University and the University of Florida have issued urgent warnings about the proliferation of 7 products and their potential for abuse, dependence, severe withdrawal, and even respiratory depression —dangers that run directly counter to it being marketed as a treatment for opioid addiction. A leading forensic research center has published public alerts on 7 products. Dr. White cautions, 'Selling potent opioid receptor-stimulating 7 products in gas stations, convenience stores, and smoke shops in unlimited quantities within arm's reach of candy bars and energy drinks is a public health recipe for disaster. It allows a whole new generation of consumers to potentially get hooked on opioids, and we know where that leads.' The KCAC's position papers in total provide lawmakers a roadmap based on the best available published evidence to protect consumers while still maintaining access to natural kratom products and runs counter to unsubstantiated pseudo-scientific claims. Download the full position paper here. About Kratom Consumer Advisory Council (KCAC) Kratom Consumer Advisory Council (KCAC) is an independent board made up of a clinician-scientist and consumers that uses the strongest available evidence to produce position statements that promote evidence-based policy. The KCAC is supported by the Global Kratom Coalition which advocates for regulations that protect consumers and curbs the sale of adulterated or synthetic products falsely marketed as kratom. For more information, visit Media Contact Dr. C. Michael White [email protected] ### SOURCE: Kratom Consumer Advisory Council (KCAC) Copyright 2025 EZ Newswire
Associated Press
an hour ago
- Associated Press
Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101
La Palma, CA June 24, 2025 --( )-- Next-generation CD47 inhibitor advances toward human trials in U.S. and Korea, with the prospect of safer, more potent immunotherapy. Since its Nasdaq debut earlier this year, Liminatus Pharma has been preparing to redefine the immune-oncology landscape with IBA101, a novel CD47 checkpoint inhibitor engineered to eliminate the anemia and thrombocytopenia that halted earlier candidates. By sparing red blood cells and platelets through targeted epitope selection and Fc engineering, IBA101 enables higher dosing levels—potentially unlocking more robust anti‑tumor responses without compromising patient safety. Behind the scenes, the company is preparing its IND-enabling package after completing pivotal GLP toxicology and pharmacology studies in non‑human primates at Charles River Laboratories, as well as downstream process development for clinical‑grade production. These data indicated that IBA101 did not induce clinically meaningful reductions in hemoglobin or platelet counts, clearing the path for simultaneous submissions to the U.S. Food and Drug Administration (FDA) and Korea's Ministry of Food and Drug Safety (MFDS) in the second half of 2026. Liminatus anticipates site activations and patient screening to begin in early 2027. Building on a Dual-Axis Mechanism IBA101 leverages a two-pronged approach: it blocks CD47—the 'don't‑eat‑me' signal—on tumor cells to reactivate macrophage‑mediated clearance, and it remodels the tumor microenvironment by enhancing macrophage turnover and antigen presentation. This innate immune activation primes T cells to exert more potent cytotoxicity. In preclinical combination studies, pairing IBA101 with PD‑1/PD‑L1 inhibitors resulted in significant increases in complete response rates versus monotherapy, bolstering expectations for superior clinical efficacy. A Strategic Collaboration in Seoul Liminatus has partnered with Dr. Se-Hoon Lee, a leading lung cancer specialist at Samsung Medical Center in Seoul, South Korea. This partnership secures access to advanced non‑small‑cell lung cancer patients and state‑of‑the‑art translational laboratories. Serial tumor biopsies, immune‑cell phenotyping, and multimodal omics analyses will be integrated into the Phase 1 protocol, which features a 3 + 3 dose‑escalation design followed by expansion cohorts and adaptive combination arms with approved PD‑1/PD‑L1 agents. The trial will focus on elucidating the specific conditions under which the combination of IBA101 and PD‑1/PD‑L1 blockade delivers superior anti‑tumor efficacy, and Dr. Sehoon Lee is the ideal partner to lead this purpose‑driven research. Lessons from Early CD47 Efforts Interest in CD47 blockade has been intense but challenging. Gilead acquired Forty Seven Inc., the primary asset for which was a CD47 blockade [technology][patent] and Pfizer signed a licensing deal for a CD47 blockade [patent], but both programs were paused due to severe anemia and thrombocytopenia caused by off‑target binding to red blood cells and platelets. By contrast, IBA101 selectively binds CD47 epitopes on tumor and immune cells: additional glycosylation on RBC and platelet CD47 proteins prevents IBA101 engagement, minimizing off‑target interactions and reducing the risk of cytopenias. Preclinical primate data suggest this design will translate into a markedly improved safety profile in humans. Top row: intact RBC pellets with clear supernatant after IBA101 treatment (no hemolysis). Bottom row: diffuse red supernatant in control wells (RBC lysis). Beyond Cancer: Toward Chronic Inflammation While oncology is the primary focus, Liminatus is also exploring IBA101's potential in chronic inflammatory diseases. Early mechanistic studies in humanized mouse models are underway to evaluate whether macrophage activation can clear senescent cells and pro‑inflammatory debris—hallmarks of age‑related conditions such as atherosclerosis and neurodegeneration. Although these investigations remain exploratory, they establish a foundation for future indication expansion. Economic Upside and Market Context Global PD‑1/PD‑L1 sales exceeded $30 billion in 2024, but looming patent expirations will invite biosimilar competition. Combining CD47 blockade technology with PD‑1/PD‑L1 therapies offers two key advantages: enhanced response rates in combination regimens and a fresh patent lifecycle to extend commercial value. Liminatus projects that a successful IBA101 launch could secure a significant share of the post‑patent market. Looking Ahead With a Nasdaq listing, a robust nonclinical data package, and strategic clinical partnerships in Korea and the United States, Liminatus Pharma is poised to enter the clinic in 2027. With safety and synergy at its core, IBA101 aims to fulfill the long‑awaited promise of CD47 blockade and usher in a new era of combination immunotherapy. About IBA101 IBA101 is a second‑generation CD47 blockade antibody licensed from InnobationBio (Seoul, South Korea). IBA101 minimizes erythrocyte and platelet binding, thereby avoiding the severe cytopenias that plagued first‑generation agents. By enhancing macrophage activation and antigen presentation, IBA101 complements adaptive checkpoint inhibitors such as PD‑1/PD‑L1 antibodies and may offer broader applications in chronic inflammatory diseases. About Liminatus Pharma Liminatus Pharma (Nasdaq: LIMN) is a preclinical‑stage immuno‑oncology company advancing IBA101 toward best‑in‑human trials. Building on over a decade of CD47 research and lessons learned from industry setbacks, Liminatus's mission is to develop next‑generation immunotherapies that restore immune balance—bridging innate and adaptive immunity to drive safer, more durable anti‑tumor responses. Forward-Looking Statements Certain statements in this press release constitute forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding management's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: · the success of clinical trials · the ability of Liminatus to raise financing in the future; · the attraction and retention of qualified directors, officers, employees and key personnel of Liminatus; · the ability of Liminatus to execute its business plans and strategy; · the ability of Liminatus to compete effectively in a highly competitive market; · the competition from larger pharmaceutical and biotechnology companies that have greater resources, · The success of competing therapies and products that are or may become available; · the costs, timing, and results of Liminatus's preclinical studies and clinical trials, as well as the number of required trials for regulatory approval and the criteria for success in such trials; · legal and regulatory developments in the United States, or U.S., and foreign countries, including any actions or advice that may affect the design, initiation, timing, continuation, progress, or outcome of clinical trials or result in the need for additional clinical trials; · cost of complying with current laws and regulations, and any changes in applicable laws or regulations; · The ability to protect and enhance Liminatus's corporate reputation and brand. · The impact of future regulatory, judicial, and legislative changes in Liminatus's industry; · The ability of Liminatus to obtain and maintain regulatory approval of any of its product candidates; · The ability of Liminatus to research, discover, and develop additional product candidates; · risks related to manufacturing active pharmaceutical ingredients, drug products, and other materials we need; · the performance of third parties upon which Liminatus depends, including contract research organizations, contract manufacturing organizations, contract laboratories, and independent contractors; · The ability of Liminatus to grow and manage growth profitably. · The ability of Liminatus to obtain and maintain intellectual property protection and not infringe on the rights of others. · The ability of Liminatus to limit its exposure under product liability lawsuits; · The inability to develop and maintain effective internal controls; · The impact of pandemics and other similar disruptions in the future. · those factors set forth in documents of Liminatus filed, or to be filed, with the SEC; and · Other factors that Liminatus may not have identified or quantified. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects. Future developments affecting Liminatus may not be those that Liminatus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of Liminatus), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Liminatus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws. In addition, statements that 'we believe' and similar statements reflect beliefs and opinions on the relevant subject. These statements are based upon information available to Liminatus as of the date of this press release, and while Liminatus believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that Liminatus has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements as predictions of future results. Liminatus's actual future results may be materially different from what it expects. Liminatus qualifies all forward-looking statements by these cautionary statements. For more information, please contact: Chris Kim, Chief Executive Officer [email protected] Contact Liminatus Pharma, Inc Chris Kim 213-273-5453 Contact Information: Liminatus Pharma, Inc Chris Kim 213-273-5453 Contact via Email Read the full story here: Liminatus Pharma Charts Dual-Front Attack on Cancer with IBA101 Press Release Distributed by
Associated Press
an hour ago
- Associated Press
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects Sanofi's commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Alyssa Johnsen Global Therapeutic Area Development Head, Immunology and Inflammation, Sanofi 'Orphan drug designation for riliprubart marks an important milestone in our mission to address critical challenges in transplant medicine leveraging our expertise in immunology. Antibody mediated rejection represents a serious threat to transplanted organs and patient survival. Through riliprubart's innovative mechanism of action, we hope to bring forward a treatment option that could significantly improve outcomes for kidney transplant recipients.' Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients ( NCT05156710 ). The study includes two patient cohorts: those at risk of developing rejection and those with active forms of antibody-mediated rejection. In addition, Sanofi is conducting two phase 3 studies exploring riliprubart in chronic inflammatory demyelinating polyneuropathy (CIPD), a rare neurological disorder, specifically in patients refractory to standard of care (MOBILIZE, clinical study identifier: NCT06290128 ), and in IVIg-treated patients (VITALIZE, clinical study identifier: NCT06290141 ). The broad clinical development program for riliprubart emphasizes Sanofi's commitment to exploring riliprubart's potential across multiple immune-mediated conditions with high unmet medical needs. About Riliprubart SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies, please visit About AMR Antibody-mediated rejection is a serious complication that may arise after solid organ transplantation, occurring when the recipient's immune system produces antibodies that attack the transplanted organ. Sensitized recipients, who have pre-existing antibodies that target foreign antigens including those found on transplanted organs, face a high risk of developing antibody-mediated rejection. Subsequent immune response can lead to inflammation, organ damage, and organ failure if left untreated. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media Relations Sandrine Guendoul | +33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Léo Le Bourhis | +33 6 75 06 43 81 | [email protected] Victor Rouault | +33 6 70 93 71 40 | [email protected] Timothy Gilbert | +1 516 521 2929 | [email protected] Léa Ubaldi | +33 6 30 19 66 46 | [email protected] Investor Relations Thomas Kudsk Larsen | +44 7545 513 693 | [email protected] Alizé Kaisserian | +33 6 47 04 12 11 | [email protected] Felix Lauscher | +1 908 612 7239 | [email protected] Keita Browne | +1 781 249 1766 | [email protected] Nathalie Pham | +33 7 85 93 30 17 | [email protected] Tarik Elgoutni | +1 617 710 3587 | [email protected] Thibaud Châtelet | +33 6 80 80 89 90 | [email protected] Yun Li | +33 6 84 00 90 72 | [email protected] Sanofi forward-looking statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment
